ReposiTrak (TRAK) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed May 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TRAK SEC filings page.
ReposiTrak (TRAK) reported $23.5M in revenue over the twelve months to Mar 31, 2026, up 6.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cash-generative, low-capital-intensity operations convert modest revenue growth into expanding margins while returning capital to shareholders.
Between FY2023 and FY2025, revenue rose from$19.1M to$22.6M , while the operating margin also widened, pointing to improving cost absorption or business mix rather than volume growth alone. Meanwhile, operating cash flow exceeded net income and nearly equaled free cash flow, showing earnings quality with little reinvestment drag.
FY2025 liabilities were
Free-cash-flow margin reached
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of ReposiTrak's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
ReposiTrak has an operating margin of 27.6%, meaning the company retains $28 of operating profit per $100 of revenue. This strong profitability earns a score of 95/100, reflecting efficient cost management and pricing power. This is up from 24.6% the prior year.
ReposiTrak's revenue grew 10.5% year-over-year to $22.6M, a solid pace of expansion. This earns a growth score of 62/100.
ReposiTrak carries a low D/E ratio of 0.01, meaning only $0.01 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 6.09, ReposiTrak holds $6.09 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 94/100.
ReposiTrak converts 37.2% of revenue into free cash flow ($8.4M). This strong cash generation earns a score of 97/100.
ReposiTrak earns a strong 14.1% return on equity (ROE), meaning it generates $14 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 79/100. This is up from 12.7% the prior year.
ReposiTrak scores 15.72, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($141.9M) relative to total liabilities ($5.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
ReposiTrak passes 6 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, ReposiTrak generates $1.21 in operating cash flow ($8.4M OCF vs $7.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
ReposiTrak earns $127.94 in operating income for every $1 of interest expense ($6.2M vs $49K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
ReposiTrak generated $5.9M in revenue in Q3 2026. This represents a decrease of 0.5% from the same quarter a year earlier. Against the prior quarter it is up 0.5%.
ReposiTrak's EBITDA was $2.3M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 9.8% from the same quarter a year earlier. Against the prior quarter it is up 15.0%.
ReposiTrak reported $2.0M in net income in Q3 2026. This represents an increase of 1.0% from the same quarter a year earlier. Against the prior quarter it is up 17.8%.
ReposiTrak earned $0.10 per diluted share (EPS) in Q3 2026. That is unchanged from the same quarter a year earlier. Against the prior quarter it is up 11.1%.
Cash & Balance Sheet
ReposiTrak generated $2.1M in free cash flow in Q3 2026, representing cash available after capex. This represents an increase of 46.1% from the same quarter a year earlier. Against the prior quarter it is down 6.9%.
ReposiTrak held $26.4M in cash against $115K in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Margins & Returns
ReposiTrak's gross margin was 86.3% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 1.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.9 percentage points.
ReposiTrak's operating margin was 38.3% in Q3 2026, reflecting core business profitability. This is up 7.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.3 percentage points.
ReposiTrak's net profit margin was 33.8% in Q3 2026, showing the share of revenue converted to profit. This is up 0.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.0 percentage points.
ReposiTrak's ROE was 3.9% in Q3 2026, measuring profit generated per dollar of shareholder equity. This is down 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.5 percentage points.
Capital Allocation
ReposiTrak spent $550K on share buybacks in Q3 2026, returning capital to shareholders by reducing shares outstanding. Against the prior quarter it is down 49.9%.
ReposiTrak reported no capital expenditure in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.
Not reported for Q3 2026.
TRAK Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.9M-0.5% | $5.9M+6.7% | $6.0M+9.7% | $5.8M+11.1% | $5.9M+16.3% | $5.5M+7.1% | $5.4M+7.5% | $5.2M+7.9% |
| Cost of Revenue | $803K-11.9% | $854K-14.8% | $854K-0.6% | $908K+7.4% | $912K+9.6% | $1.0M+3.0% | $859K+12.1% | $845K+9.8% |
| Gross Profit | $5.1M+1.6% | $5.0M+11.5% | $5.1M+11.7% | $4.9M+11.9% | $5.0M+17.6% | $4.5M+8.1% | $4.6M+6.7% | $4.3M+7.5% |
| SG&A Expenses | $1.4M-5.4% | $1.5M+6.6% | $1.4M+6.2% | $1.5M+9.4% | $1.5M+7.6% | $1.4M+2.2% | $1.3M+1.0% | $1.4M+4.5% |
| Operating Income | $2.3M+24.5% | $1.8M+34.4% | $1.9M+28.0% | $1.6M+20.1% | $1.8M+43.3% | $1.4M+9.0% | $1.5M+23.3% | $1.3M+13.4% |
| EBITDA | $2.3M+9.8% | $2.0M+23.2% | $2.1M+21.4% | $1.9M+19.3% | $2.1M+37.8% | $1.7M+7.5% | $1.8M+16.7% | $1.6M+9.4% |
| Interest Expense | $9K-28.3% | $9K-21.8% | $11K+11.4% | $14K+119.8% | $13K+59.5% | $12K+58.8% | $10K+60.3% | $6K-27.0% |
| Income Tax | $450K+200.1% | $450K+195.8% | $450K+200.0% | $224K+123.8% | $150K+149.9% | $152K+33.4% | $150K+49.3% | $100K+141.8% |
| Net Income | $2.0M+1.0% | $1.7M+8.7% | $1.8M+9.3% | $1.8M+13.8% | $2.0M+26.8% | $1.6M+6.9% | $1.7M+20.8% | $1.6M+14.6% |
| EPS (Basic) | $0.11+10.0% | $0.09+12.5% | $0.10+11.1% | $0.09+12.5% | $0.10+25.0% | $0.08+14.3% | $0.09+28.6% | $0.08+14.3% |
| EPS (Diluted) | $0.100.0% | $0.09+12.5% | $0.09+12.5% | $0.09+12.5% | $0.10+25.0% | $0.08+14.3% | $0.08+14.3% | $0.08+14.3% |
| Diluted Shares (Avg) | 19M-1.6% | 19M-0.5% | 19M+0.1% | N/A | 19M+1.0% | 19M+1.8% | 19M+1.4% | N/A |
Not reported in any period shown, so not listed: R&D Expenses.
TRAK Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $57.4M+4.6% | $56.3M+2.9% | $55.6M+6.3% | $55.3M+7.2% | $54.8M+6.8% | $54.7M+8.8% | $52.3M+4.2% | $51.6M+2.0% |
| Current Assets | $33.1M+1.1% | $35.0M+7.9% | $34.1M+13.4% | $33.7M+15.0% | $32.8M+13.6% | $32.4M+17.5% | $30.1M+10.6% | $29.3M+7.4% |
| Cash & Equivalents | $26.4M-6.1% | $28.7M+2.4% | $28.8M+11.7% | $28.6M+13.6% | $28.1M+15.1% | $28.0M+20.6% | $25.8M+8.8% | $25.2M+4.8% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Receivable | $5.1M+41.7% | $4.9M+43.8% | $4.3M+31.6% | $4.1M+12.4% | $3.6M-4.7% | $3.4M-11.2% | $3.3M+9.1% | $3.7M+45.8% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $20.9M0.0% | $20.9M0.0% | $20.9M0.0% | $20.9M0.0% | $20.9M | $20.9M | $20.9M | $20.9M0.0% |
| Total Liabilities | $6.9M+16.4% | $6.6M-3.1% | $5.4M+13.2% | $5.8M+22.5% | $5.9M+21.7% | $6.8M+48.3% | $4.8M+4.3% | $4.7M+0.9% |
| Current Liabilities | $6.8M+24.5% | $6.4M+2.7% | $5.2M+17.0% | $5.5M+21.7% | $5.4M+17.0% | $6.3M+46.4% | $4.5M+4.2% | $4.5M+7.3% |
| Non-Current Liabilities | $115K-76.0% | $170K-69.0% | $225K-35.3% | $279K+40.1% | $479K+122.2% | $549K+74.0% | $348K+5.7% | $199K-57.6% |
| Long-Term Debt | $115K-65.4% | $170K-55.6% | $225K+35.8% | $279K | $332K | $384K | $166K | $0-100.0% |
| Total Equity | $50.5M+3.2% | $49.7M+3.7% | $50.2M+5.6% | $49.5M+5.7% | $48.9M+5.3% | $47.9M+4.8% | $47.5M+4.2% | $46.9M+2.1% |
| Retained Earnings | -$8.7M+38.6% | -$10.3M+34.5% | -$11.5M+31.4% | -$12.8M+28.5% | -$14.2M+25.2% | -$15.7M+21.9% | -$16.8M+20.5% | -$18.0M+18.5% |
Not reported in any period shown, so not listed: Inventory.
TRAK Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.1M+45.2% | $2.2M-35.3% | $1.5M-17.7% | $1.7M-19.3% | $1.4M-41.6% | $3.5M+271.5% | $1.9M+22.9% | $2.1M+14.5% |
| Depreciation & Amortization | $95K-71.0% | $224K-26.5% | $244K-13.0% | $338K+15.7% | $329K+13.9% | $305K+1.6% | $280K-9.3% | $292K-5.4% |
| Stock-Based Compensation | N/A | N/A | $101K+1.0% | N/A | N/A | N/A | $100K+17.2% | N/A |
| Capital Expenditures | $0-100.0% | -$1 | $12K | $7K-87.1% | $9K+25.5% | $0-100.0% | $0 | $56K |
| Free Cash Flow | $2.1M+46.1% | $2.2M-35.3% | $1.5M-18.3% | $1.6M-17.4% | $1.4M-41.8% | $3.5M+275.8% | $1.9M+22.9% | $2.0M+11.4% |
| Investing Cash Flow | -$3.0M-24046.3% | $21+100.1% | -$20K-159.7% | -$6K+88.2% | -$13K+60.9% | -$15K+7.4% | $34K | -$52K |
| Financing Cash Flow | -$1.3M-1.5% | -$2.3M-95.0% | -$1.3M-2.0% | -$1.2M+6.5% | -$1.3M-8.3% | -$1.2M+12.2% | -$1.3M+30.2% | -$1.3M-74.6% |
| Dividends Paid | $411K-19.5% | $424K+3.8% | $403K-4.7% | $314K-27.8% | $510K+14.4% | $409K-2.4% | $423K+0.4% | $435K+3.1% |
| Share Buybacks | $550K | $1.1M+998.4% | $150K | $100K | $0 | $100K-48.3% | $0-100.0% | $0-100.0% |
TRAK Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.3%+1.8pp | 85.4%+3.7pp | 85.7%+1.5pp | 84.2%+0.5pp | 84.6%+0.9pp | 81.7%+0.7pp | 84.2%-0.7pp | 83.7%-0.3pp |
| Operating Margin | 38.3%+7.7pp | 31.0%+6.4pp | 31.7%+4.5pp | 27.5%+2.0pp | 30.6%+5.8pp | 24.6%+0.4pp | 27.2%+3.5pp | 25.5%+1.2pp |
| Net Margin | 33.8%+0.5pp | 28.8%+0.5pp | 30.5%-0.1pp | 31.2%+0.7pp | 33.2%+2.7pp | 28.2%-0.1pp | 30.6%+3.4pp | 30.4%+1.8pp |
| Return on Equity | 3.9%-0.1pp | 3.4%+0.2pp | 3.6%+0.1pp | 3.6%+0.3pp | 4.0%+0.7pp | 3.2%+0.1pp | 3.5%+0.5pp | 3.4%+0.4pp |
| Return on Assets | 3.5%-0.1pp | 3.0%+0.2pp | 3.3%+0.1pp | 3.3%+0.2pp | 3.6%+0.6pp | 2.8%-0.1pp | 3.2%+0.4pp | 3.1%+0.3pp |
| Current Ratio | 4.89-1.1x | 5.45+0.3x | 6.54-0.2x | 6.09-0.4x | 6.03-0.2x | 5.18-1.3x | 6.75+0.4x | 6.450.0x |
| Debt-to-Equity | 0.000.0x | 0.000.0x | 0.000.0x | 0.010.0x | 0.01-0.1x | 0.01-0.1x | 0.00-0.1x | 0.000.0x |
| Asset Turnover | 0.100.0x | 0.100.0x | 0.110.0x | 0.100.0x | 0.110.0x | 0.100.0x | 0.100.0x | 0.100.0x |
| FCF Margin | 35.4%+11.3pp | 38.2%-24.8pp | 25.6%-8.8pp | 28.6%-9.9pp | 24.1%-24.1pp | 63.0%+45.1pp | 34.4%+4.3pp | 38.6%+1.2pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| ReposiTrak TRAK | FY2025 | $22.6M | $7.0M | 30.9% | $141.9M | 88/100 |
| A2Z Cust2Mate Solutions Corp AZ | FY2025 | $7.9M | -$38.5M | N/A | $270.8M | 18/100 |
| 8X8 Inc EGHT | FY2026 | $735.8M | $1.6M | 0.2% | $273.0M | 32/100 |
| Agora, Inc. API | FY2025 | $141.1M | $9.5M | 6.8% | $358.5M | 70/100 |
| Blaize Holdings BZAI | FY2025 | $38.6M | -$206.9M | N/A | $66.7M | 37/100 |
Where ReposiTrak Ranks
Frequently Asked Questions
What is ReposiTrak's annual revenue?
ReposiTrak (TRAK) reported $22.6M in total revenue for fiscal year 2025. This represents a 10.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is ReposiTrak's revenue growing?
ReposiTrak (TRAK) revenue grew by 10.5% year-over-year, from $20.5M to $22.6M in fiscal year 2025.
Is ReposiTrak profitable?
Yes, ReposiTrak (TRAK) reported a net income of $7.0M in fiscal year 2025, with a net profit margin of 30.9%.
What is ReposiTrak's EBITDA?
ReposiTrak (TRAK) had EBITDA of $7.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does ReposiTrak have?
As of fiscal year 2025, ReposiTrak (TRAK) had $28.6M in cash and equivalents against $279K in long-term debt.
What is ReposiTrak's gross margin?
ReposiTrak (TRAK) had a gross margin of 83.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is ReposiTrak's operating margin?
ReposiTrak (TRAK) had an operating margin of 27.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is ReposiTrak's net profit margin?
ReposiTrak (TRAK) had a net profit margin of 30.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is ReposiTrak's return on equity (ROE)?
ReposiTrak (TRAK) has a return on equity of 14.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is ReposiTrak's free cash flow?
ReposiTrak (TRAK) generated $8.4M in free cash flow during fiscal year 2025. This represents a 22.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is ReposiTrak's operating cash flow?
ReposiTrak (TRAK) generated $8.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are ReposiTrak's total assets?
ReposiTrak (TRAK) had $55.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are ReposiTrak's capital expenditures?
ReposiTrak (TRAK) invested $16K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is ReposiTrak's current ratio?
ReposiTrak (TRAK) had a current ratio of 6.09 as of fiscal year 2025, which is generally considered healthy.
What is ReposiTrak's debt-to-equity ratio?
ReposiTrak (TRAK) had a debt-to-equity ratio of 0.01 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is ReposiTrak's return on assets (ROA)?
ReposiTrak (TRAK) had a return on assets of 12.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is ReposiTrak's P/E ratio?
ReposiTrak (TRAK) trades at 19.5x earnings, its market capitalization divided by net income of $7.3M net income, trailing 12 months to March 31, 2026. The market capitalization is $141.9M as of Sep 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is ReposiTrak's price-to-sales ratio?
ReposiTrak (TRAK) trades at 6.0x sales, its market capitalization divided by revenue of $23.5M revenue, trailing 12 months to March 31, 2026. The market capitalization is $141.9M as of Sep 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is ReposiTrak's Altman Z-Score?
ReposiTrak (TRAK) has an Altman Z-Score of 15.72, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is ReposiTrak's Piotroski F-Score?
ReposiTrak (TRAK) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are ReposiTrak's earnings high quality?
ReposiTrak (TRAK) has an earnings quality ratio of 1.21x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can ReposiTrak cover its interest payments?
ReposiTrak (TRAK) has an interest coverage ratio of 127.94x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is ReposiTrak?
ReposiTrak (TRAK) scores 88 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.